Apactron completes nearly 1 billion Series B financing, leading a new era in China-developed particle therapy

Recently, Apactron announced the successful completion of a nearly 1 billion Series B financing round. This round was jointly led by New Alliance Capital, Cenova Capital, Fortera Capital (affiliated with Shanghai State-owned Capital Investment) and Shanghai STVC Group, along with China Pacific Insurance. Participating follow-on investors included SII, Atlas Venture, Zizhu Fengwu, Juhua Hefeng, Real Power Capital, Songqing Capital, Jiading Industrial Zone, Zhongke Park, Xuhui STVC, and Wenzhou State-owned Capital Investment, among others. Notably, market-oriented capital accounted for over two-thirds of the total funding in this round, reflecting strong market recognition and support for Apactron's growth prospects. Additionally, Apactron's controlling shareholder, Shanghai Alliance Investment, continued to contribute additional investment, further empowering the company's long-term development.

 Apactron's Manufacturing and R&D Industrialization Base

Apactron stated that the funds raised in this round will be primarily allocated to upgrading core technology R&D, expanding its product portfolio, and strengthening its market network, thereby further solidifying its leading position in China's domestic particle therapy equipment sector and promoting innovation and healthy development within the industry.

As a pioneer in the field of particle therapy, Apactron has consistently adhered to its development mission of "grounded in independent innovation, building high-end domestic particle therapy technology in China, benefiting domestic cancer patients, and supporting the Healthy China strategy." Apactron actively explores an innovative integrated model of "government, industry, academia, research, finance, service, and application." In September 2022, Apactron successfully obtained approval for China's first and currently only registered domestic proton therapy system, which achieves a localization rate of 95% and delivers overall performance at an internationally advanced level. Since its deployment at the Ruijin Proton Center in late 2023, the system has provided treatment to over 1,000 patients, covering more than 50 tumor types, including over 50 pediatric and adolescent cancer patients (with the youngest being 3 years old), and has demonstrated positive clinical outcomes.

 360° Full Rotation Beam Therapy System

While advancing the optimization and application of its existing system, Apactron is actively promoting the registration process for new treatment units. The company's second registration unit—a 360-degree rotating treatment room—has been granted an exemption from clinical trials by the National Medical Products Administration and has already submitted its registration application. It is expected to be officially put into clinical use after the Spring Festival.

 All-Solid-State Power Source Proton Injector

Furthermore, Apactron has successfully independently developed a compact synchrotron and an all-solid-state power source proton injector, reducing the accelerator's footprint from the original 270 square meters to 120 square meters, significantly enhancing space utilization efficiency. Apactron has also adopted advanced technologies such as Lambertson magnets, effectively lowering the equipment's energy consumption. By overcoming a series of key technical challenges including helium-free superconducting magnets and a miniaturized rotating gantry, the new-generation rotating gantry weighs less than 40 tons, with a diameter under 7 meters and a length under 6 meters, achieving structural compactness and lightweight design. While ensuring that core performance parameters—such as field size, dose rate, and rotation angle—remain unaffected, the single-room treatment system's footprint has been reduced to approximately 400 square meters. These breakthroughs not only elevate the technological level and application efficiency of the existing system but also lay a solid foundation for the development of the next generation of modular, multi-particle, and miniaturized treatment systems.

 Prototype of Superconducting Liquid-Helium-Free Deflection Magnet